secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2026-05-15T21:10:20+00:00
Accession:  0001193125-26-227204
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA Q1 cash $6.3M; secures $50M credit facility; IFx-2.0 gets ODD in melanoma
--------------------------------------------------------------------------------

- Cash and equivalents $6.3M at March 31, 2026; net operating cash outflow $4.4M in Q1.
- Established $50M credit facility with largest stockholder at 12% interest, maturing 2031; extends runway into 2028.
- R&D expenses $5.2M (up from $4.6M YoY); G&A $2.3M (up from $2.0M YoY).
- FDA Orphan Drug Designation granted for IFx-2.0 in stage IIB-IV melanoma.
- Appointed Craig Tendler as CMO and Amanda Garofalo as SVP Clinical Operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/0001193125-26-227204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/hura-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-227204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer